FDA approves Vyalev for advanced Parkinson's disease
The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
pharmaphorum6d
AbbVie gets continuous Parkinson's drug over the line in US
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...
FiercePharma6d
3rd time's the charm: AbbVie scores FDA nod for continuous Parkinson's disease therapy Vyalev
AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...
Hosted on MSN5d
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in ...
Crain's Chicago Business6d
New AbbVie Parkinson’s drug finally gets green light to hit U.S. market
After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...
AbbVie: Expect A Beat-And-Raise Q3 2024
AbbVie should report strong Q3 2024 results next week and increase the full-year guidance. Explore more details here.
After rejections, AbbVie secures approval for Parkinson’s drug
Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired ...
McKnight's Long-Term Care News4d
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
The FDA approved AbbVie's Vyalev as the first 24-hour subcutaneous infusion therapy for advanced Parkinson's disease, ...
GlobalData on MSN6d
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor ...
Yahoo Finance6d
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
For AbbVie, the 200-day moving average sits at $176.24, according to Benzinga Pro, which is below the current price of $189.49. For more on charts and trend lines, see a description here.